Early Detection Techniques Change the Dynamics of the Systemic Fungal Infection Therapeutics Market, Finds Frost & Sullivan

SINGAPORE, April 20 /PRNewswire/ -- Over the next five years, technological advancements in therapeutics are expected to amplify the number of patients diagnosed with systemic fungal infection (SFI) in Thailand. The significant increase in number of patients is shifting the focus of managing SFI from empiric and prophylactic methods to targeted and pre-emptive treatment.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), Systemic Fungal Infection Therapeutics Market – Thailand, estimates that the global prevalence of SFI has risen to four for every one thousand of the global population. Similarly, the incidence of SFI has increased steadily over the years due to the widespread use of broad-spectrum antibiotics, which reduce non-pathogenic bacterial population that compete with fungi, and the increased number of persons with compromised immune systems caused by AIDS, immunosuppressant drugs, and chemotherapy agents.

The SFI therapeutics market is also likely to receive a shot in the arm with a high premium on products that are capable of tackling emergent, problematic pathogens. As more resistant pathogens in SFI emerge, therapy will revolve around ensuring that the right treatment is administered. This is made possible through non-microbiologic and clinical diagnostic techniques (Platelia, Fungitell, and PNA FISH®) to identify the onset of infection.

Although there are key therapeutics to treat the most causative pathogen (Candida Albicans), there is still an unmet need to treat more resistant pathogens such as Aspergillus. Doctors are under increasing pressure to ensure that they choose the right course of treatment the first time, based on the universal criteria of risk factors, clinical, radiological, microbiological, or other diagnostic evidence.

"This places greater emphasis on matching antifungal choice to pathogen susceptibility, increasing the demand for rapid typing of pathogens to ensure informed, targeted drug choices," says Frost & Sullivan Program Manager Carole Gaffud. "As a result, there would be a reduction in the use of prophylaxis in the 'at risk' patient group, and empiric therapy in patients groups with a persistent fever or other suggestive symptoms."

Given the relatively niche nature of SFI, it is important for key participants to differentiate their products, especially as advancements in diagnostic techniques restrict prescriptions to specific therapeutic uses. As therapeutics shift from broad and empiric indications, pharmaceutical manufacturers need to position their products to address more specific indications defined by pathogen species (and subspecies) and patient population. This enables greater differentiation, thereby protecting the specific drug from generic erosion in the future.

"The changing epidemiology of causative pathogens has caused a decline in the effectiveness of existing therapeutic options," notes Gaffud. "Pharmaceutical manufacturers need to develop drugs that address specific indications, in terms of pathogen coverage and patient groups (solid organ transplant patients, cancer patients, neonates, HIV/AIDS patients, and surgery patients)."

If you are interested in more information on this study, please send an e-mail to Nicklaus Au, Corporate Communications, at [email protected] and [email protected] with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Systemic Fungal Infection Therapeutics Market – Thailand is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: The Systemic Fungal Infection Therapeutics Market in Hong Kong, The Systemic Fungal Infection Therapeutics Market in China, The Systemic Fungal Infection Therapeutics Market in Australia, The Systemic Fungal Infection Therapeutics Market in Singapore, The Systemic Fungal Infection Therapeutics Market in India, The Systemic Fungal Infection Therapeutics Market in Taiwan, The Systemic Fungal Infection Therapeutics Market in Malaysia, The Systemic Fungal Infection Therapeutics Market in the Philippines, and The Systemic Fungal Infection Therapeutics Market in South Korea. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

SOURCE Frost & Sullivan